Showing 1 - 10 of 14,106
This WTO working paper studies availability and affordability of new and innovative pharmaceuticals in a post-TRIPS era …. The WTO's TRIPS Agreement (TRIPS) makes it obligatory for WTO members − except least-developed country members (LDCs) - to … to be compliant with this provision of TRIPS by 2005. This study investigates two questions in this context: (1) How does …
Persistent link: https://www.econbiz.de/10011992779
This paper analyses the causal impact of Intellectual Property Rights (IPR) on pharmaceutical innovation in a panel of 74 countries. The identification strategy exploits the different timing across countries of two sets of IPR reforms. Domestic innovation is measured as citation-weighted...
Persistent link: https://www.econbiz.de/10011509446
Persistent link: https://www.econbiz.de/10012433548
Persistent link: https://www.econbiz.de/10012433661
Persistent link: https://www.econbiz.de/10012433977
Persistent link: https://www.econbiz.de/10012518985
Persistent link: https://www.econbiz.de/10012433673
Are IPRs institutions meant to foster innovative activities or conversely to secure appropriation and profitability? Taking stock of a long-term empirical evidence on the pharmaceutical sector in the US, we can hardly support IPRs intended as an innovation rewarding institution. According to our...
Persistent link: https://www.econbiz.de/10012604733
Persistent link: https://www.econbiz.de/10011963838